Author: Dr Kenneth Wong, Dermatology Registrar, Greenlane Hospital, Auckland, New Zealand, 2008.
Autoimmune progesterone dermatitis is a rare skin condition in women that recurs in a cyclical manner corresponding to their menstrual cycles. It is thought to be a response of the skin to the hormonal changes that happen just before menses. The skin rash is an autoimmune response to the body's progesterone, hence its name.
The cause of autoimmune progesterone dermatitis is not entirely understood. Some patients have had previous exposure to external progesterone in the form of oral contraceptive pills. This is thought to pre-sensitise patients to react against their internal progesterone. However, not all patients with autoimmune progesterone dermatitis are exposed to previous hormone therapy. It has been postulated that these patients produce an altered form of progesterone that incites an immunologic response against it. In another theory, progesterone is thought to heighten a patient's hypersensitivity response to another allergen.
Characteristically, the skin eruptions occur during the luteal phase or the late pre-menstrual phase of the cycle. This is when the blood level of the sex-hormone progesterone rises.
Within a few days of menstruation when progesterone level falls, there is partial to complete resolution of the rash. It will recur during the next cycle.
Several other skin conditions may be more severe during the perimenstrual period, but these are not classified as autoimmune progesterone dermatitis. These include:
On average, the skin rash happens seven days before the onset of menstruation and lasts for 1–3 days after menstruation.
The age of onset is variable, the youngest case occurred at menarche, and the disease can begin as late as 48 years of age.
The diagnosis is usually made from the characteristic cyclical presentation.
A skin prick test with intradermal progesterone is helpful. Positive tests with progesterone can be fairly rapid, usually developing as urticaria within 30 minutes of inoculation, or delayed with rashes peaking at 24–48 hours.
Provocative testing with intramuscular or oral progesterone can be performed as an alternative.
Skin biopsy alone is seldom diagnostic. A variety of histological features have been described. Superficial perivascular mixed inflammation is the most consistent finding.
The production of progesterone can be suppressed with hormone-based therapy. This includes the use of conjugated oestrogen (American spelling estrogen), ethinyloestradiol, tamoxifen and danazol.
Women with autoimmune progesterone dermatitis should try to avoid medications containing progesterone including the combined oral contraceptive pill, minipill, and depo injections. The specific drugs to avoid include norethindrone, norgestrel, levonorgestrel.
Surgical removal of ovaries or oophorectomy is curative in refractory cases.
See the DermNet NZ bookstore.
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.